Myeloid Leukemia News and Research

RSS
Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

4 Jun 2011
ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

3 Jun 2011
EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

31 May 2011
Leukemia protein plays a role in Alzheimer's disease

Leukemia protein plays a role in Alzheimer's disease

25 May 2011
Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

21 May 2011
New study sheds light on origins of myeloid leukemia

New study sheds light on origins of myeloid leukemia

13 May 2011
Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

12 May 2011
Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

12 May 2011
Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

11 May 2011
EpiCept first quarter net loss decreases to $2.5 million

EpiCept first quarter net loss decreases to $2.5 million

10 May 2011
CytRx reports $6.3 million net loss for first quarter 2011

CytRx reports $6.3 million net loss for first quarter 2011

5 May 2011
ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

20 Apr 2011
Clontech releases iDimerize inducible dimerization systems

Clontech releases iDimerize inducible dimerization systems

20 Apr 2011
Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

20 Apr 2011
Novel drug holds potential against resistant chronic myeloid leukemia

Novel drug holds potential against resistant chronic myeloid leukemia

12 Apr 2011
NCI, ASH, AMEH join to improve care for patients with AML

NCI, ASH, AMEH join to improve care for patients with AML

11 Apr 2011
Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

8 Apr 2011
ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

5 Apr 2011
Positive outcomes from imatinib trial in both older and younger patients with CML

Positive outcomes from imatinib trial in both older and younger patients with CML

31 Mar 2011
Researchers develop new drug for multiple cancer treatment

Researchers develop new drug for multiple cancer treatment

30 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback